Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)
Hereditary Angioedema / Posted 10 months ago
Brief Summary
The Icatibant Outcome Survey (IOS) is a prospective, observational disease registry designed to document the routine clinical outcomes over time in participants with angioedema treated with Firazyr® (icatibant) and/or Cinryze® (C1 inhibitor [human]) in countries where it is currently approved. The data collected will be used to evaluate the safety of Firazyr (icatibant) and Cinryze (C1 inhibitor [human]) in routine clinical practice and as a data source for post-marketing investigations.
Detailed Description
The Icatibant Outcome Survey (IOS) is a multicenter, prospective, observational study for participants treated with Firazyr (icatibant) and/or Cinryze (C1 inhibitor [human]) in countries where it is currently approved. The entry of participants in the Icatibant Outcome Survey (IOS) is at the discretion of the physician and the participant and is not a pre-requisite for prescribing Firazyr (icatibant) or Cinryze (C1 inhibitor [human]).
-
Inclusion Criteria :
- Ages Eligible for Study: Child, Adult, Older Adult
- Sexes Eligible for Study: All
- Accepts Healthy Volunteers: No
- Diagnosis of at least 1 of the following:
- Hereditary angioedema (HAE) type I or II
- HAE with normal C1 inhibitor
- ACE-I-induced angioedema
- Non-histaminergic idiopathic angioedema
- Acquired angioedema.
- Signed and dated written informed consent from the participant or, for participants aged less than 18 years (or as per local regulation, such as <16 years in the United Kingdom [UK]), parent and/or participants legally authorized representative (LAR), and assent of the minor where applicable.
- At sites only participating in the drug registry, participants must have taken at least 1 dose of Firazyr (Icatibant) or Cinryze (C1 inhibitor [human]).
- Enrolled participants in Germany taking Firazyr (Icatibant) or Cinryze (C1 inhibitor [human]) will only use the respective product in accordance with the product label.
-
Exclusion Criteria :
- Participants enrolled in clinical trials where the product is blinded or where the product under investigation is for the treatment of HAE, ACE-I-induced angioedema, non-histaminergic idiopathic angioedema, or acquired angioedema.
- Participants enrolled in another Shire-sponsored registry involving products for the treatment of HAE, ACE-I-induced angioedema, non-histaminergic idiopathic angioedema, or acquired angioedema. An exception applies to participants enrolled in the Shire lanadelumab ENABLE study.
- Study end date : January 31, 2027
- Wales-Based Study Contact : Tariq El-Shanawany, MBBS, MD, MRCPCH, MSc